Traits, trends and hits of orphan drug designations in cystic fibrosis
Open Access
- 27 July 2023
- journal article
- research article
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 22 (5) , 949-957
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTRNew England Journal of Medicine, 2015
- Outcomes of EMA marketing authorization applications: does partnering have an influence?Nature Reviews Drug Discovery, 2014
- Gene therapy in cystic fibrosisArchives of Disease in Childhood, 2014
- Clinical development success rates for investigational drugsNature Biotechnology, 2014
- Rare lung disease and orphan drug developmentThe Lancet Respiratory Medicine, 2013
- Treatment of lung infection in patients with cystic fibrosis: Current and future strategiesJournal of Cystic Fibrosis, 2012
- Characteristics of orphan drug applications that fail to achieve marketing approval in the USADrug Discovery Today, 2011
- Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTRMutationNew England Journal of Medicine, 2010
- Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosisAdvanced Drug Delivery Reviews, 2002
- Effect of Aerosolized Recombinant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients with Cystic FibrosisNew England Journal of Medicine, 1994